tetano
Editor, Senior Moderator
SN Compr Clin Med
. 2022;4(1):29.
doi: 10.1007/s42399-021-01094-w. Epub 2022 Jan 10.
Eyelid Myokymia-a Presumed Manifestation of Coronavirus Disease 2019 (COVID-19)
Hashim Ali Khan[SUP] 1 2 [/SUP], Muhammad Aamir Shahzad[SUP] 3 [/SUP], Smaha Jahangir[SUP] 2 [/SUP], Junaid Iqbal[SUP] 1 [/SUP], Suhail Abbas Juwa[SUP] 1 [/SUP], Qaim Ali Khan[SUP] 4 [/SUP], Munib-Ur-Rehman[SUP] 5 [/SUP], Naeemullah Khan[SUP] 6 [/SUP], Muhammad Afzal[SUP] 7 [/SUP], Fatima Iqbal[SUP] 2 8 [/SUP]
Affiliations
Abstract
The purpose of this study is to report eyelid myokymia in patients recently recovered from COVID-19 disease. A cohort of 15 patients who developed eyelid myokymia during or immediate post-recovery of systemic disease were evaluated. Demographic, clinical characteristics, effect of age, and hospitalization on the disease course were studied. The disease course was evaluated every month for 3 months period. All, except 2, patients had complete resolution of lid myokymia within 3 months of onset. Median [IQR] myokymia recovery time was 42 [31,60] days. Age and duration of hospitalization had a significant linear relationship with myokymia recovery time. Recovery was delayed by 2.64 days with every 1-year increment in age and by 6.19 days with every additional day of hospital stay. Recovery time was independent of severity of systemic disease (P = .055) and gender (P = 0.2). Eyelid myokymia can be a possible manifestation of COVID-19 recovery phase. While myokymia recovers gradually in all these patients, older age and a longer duration of hospitalization are associated with slower recovery.
Keywords: Blepharospasm; COVID-19; Coronavirus; Eyelid myokymia.
. 2022;4(1):29.
doi: 10.1007/s42399-021-01094-w. Epub 2022 Jan 10.
Eyelid Myokymia-a Presumed Manifestation of Coronavirus Disease 2019 (COVID-19)
Hashim Ali Khan[SUP] 1 2 [/SUP], Muhammad Aamir Shahzad[SUP] 3 [/SUP], Smaha Jahangir[SUP] 2 [/SUP], Junaid Iqbal[SUP] 1 [/SUP], Suhail Abbas Juwa[SUP] 1 [/SUP], Qaim Ali Khan[SUP] 4 [/SUP], Munib-Ur-Rehman[SUP] 5 [/SUP], Naeemullah Khan[SUP] 6 [/SUP], Muhammad Afzal[SUP] 7 [/SUP], Fatima Iqbal[SUP] 2 8 [/SUP]
Affiliations
- PMID: 35036848
- PMCID: PMC8743236
- DOI: 10.1007/s42399-021-01094-w
Abstract
The purpose of this study is to report eyelid myokymia in patients recently recovered from COVID-19 disease. A cohort of 15 patients who developed eyelid myokymia during or immediate post-recovery of systemic disease were evaluated. Demographic, clinical characteristics, effect of age, and hospitalization on the disease course were studied. The disease course was evaluated every month for 3 months period. All, except 2, patients had complete resolution of lid myokymia within 3 months of onset. Median [IQR] myokymia recovery time was 42 [31,60] days. Age and duration of hospitalization had a significant linear relationship with myokymia recovery time. Recovery was delayed by 2.64 days with every 1-year increment in age and by 6.19 days with every additional day of hospital stay. Recovery time was independent of severity of systemic disease (P = .055) and gender (P = 0.2). Eyelid myokymia can be a possible manifestation of COVID-19 recovery phase. While myokymia recovers gradually in all these patients, older age and a longer duration of hospitalization are associated with slower recovery.
Keywords: Blepharospasm; COVID-19; Coronavirus; Eyelid myokymia.